Trevi Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
11analysts covering
FY EPS (est.)
-$0.48next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents and Marketable Securities Quarterly171.8MTarget: Sufficient to fund operations into 2030
Research and Development (R&D) Expenses Quarterly9.9MTarget: Manageable clinical trial spend to preserve runway
Net Loss Quarterly13.2MTarget: Minimize cash burn during late-stage clinical trials
Watch Items
- Phase 3 IPF-Related Chronic Cough Trials InitiationTrigger: First trial expected to initiate in Q2 2026, second in H2 2026Action: Monitor clinical trial registry updates and company press releases for patient enrollment milestones
- Phase 2b Refractory Chronic Cough (RCC) Trial InitiationTrigger: Expected initiation in Q2 2026Action: Track trial site activation and patient dosing progress
- Phase 2b Non-IPF ILD-Related Chronic Cough Trial InitiationTrigger: Expected initiation in H2 2026Action: Verify FDA protocol alignment and trial launch announcements
Research as of 20 Jun 2026